Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RORB | Q92753 | 3/20 | 0.49 |
| ▸ | RORC | P51449 | 2/20 | 0.49 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.46 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.44 |
| ▸ | HCRTR1 | O43613 | 10/20 | 0.43 |
| ▸ | HCRTR2 | O43614 | 10/20 | 0.43 |
| ▸ | TACR1 | P25103 | 2/20 | 0.41 |
| ▸ | KLRK1 | P26718 | 1/20 | 0.41 |
| ▸ | MICA | Q29983 | 1/20 | 0.41 |
| ▸ | S1PR5 | Q9H228 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4740974 | 0.94 | TRPV1 (0.54) | RORBRORCTRPV1CHRM3HCRTR1 | |
| SCHEMBL3063297 | 0.85 | HCRTR2 (0.50) | CHRM3HCRTR1HCRTR2 | |
| SCHEMBL1398834 | 0.84 | HCRTR1 (0.57) | HCRTR1HCRTR2 | |
| SCHEMBL1398831 | 0.84 | HCRTR1 (0.57) | HCRTR1HCRTR2 | |
| SCHEMBL3048571 | 0.83 | RORB (0.50) | RORBRORCTRPV1CHRM3HCRTR1 | |
| SCHEMBL3058147 | 0.83 | MEN1 (0.48) | CHRM3HCRTR1HCRTR2 | |
| SCHEMBL4784760 | 0.81 | HCRTR1 (0.53) | TRPV1CHRM3HCRTR1HCRTR2 | |
| SCHEMBL2930629 | 0.81 | RORB (0.46) | RORBRORCHCRTR1HCRTR2KLRK1 | |
| SCHEMBL1398791 | 0.80 | LMNA (0.54) | TACR1 | |
| SCHEMBL4740969 | 0.80 | PDK2 (0.51) | RORBRORCTRPV1CHRM3HCRTR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100222600-A1 | AZETIDINE COMPOUNDS AS OREXIN RECEPTOR ANTAGONISTS | ACTELION PHARMACEUTICALS LTD. (CH) | 2010-09-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100222600-A1 | AZETIDINE COMPOUNDS AS OREXIN RECEPTOR ANTAGONISTS | HCRTR2, HCRTR1, NPY1R | RORB 406/4885RORC 651/4885TRPV1 407/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.